Kamada, which provides plasma-derived protein therapeutics mostly in Israel and the US, raised $52 million by offering 5.6 million shares at $9.25. Kamada plans to list on the NASDAQ under the symbol KMDA. Kamada initially filed confidentially on 1/24/2013. Morgan Stanley and Jefferies & Co. acted as lead managers on the deal.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.